Efficacy and safety of XKH004, a novel dual interleukin-17A/F inhibitory monoclonal antibody, in active ankylosing spondylitis: A 52-week phase 3 randomized study
Efficacy and safety of XKH004, a novel dual interleukin-17A/F inhibitory monoclonal antibody, in active ankylosing spondylitis: A 52-week phase 3 randomized study. // hLife. – URL: https://www.sciencedirect.com/science/article/pii/S2949928326000532?dgcid=rss_sd_all
Efficacy and safety of XKH004, a novel dual interleukin-17A/F inhibitory monoclonal antibody, in active ankylosing spondylitis: A 52-week phase 3 randomized study. hLife. https://www.sciencedirect.com/science/article/pii/S2949928326000532?dgcid=rss_sd_all
“Efficacy and safety of XKH004, a novel dual interleukin-17A/F inhibitory monoclonal antibody, in active ankylosing spondylitis: A 52-week phase 3 randomized study.” hLife.
@article{article3663,
title = {Efficacy and safety of XKH004, a novel dual interleukin-17A/F inhibitory monoclonal antibody, in active ankylosing spondylitis: A 52-week phase 3 randomized study},
journal = {hLife},
url = {https://www.sciencedirect.com/science/article/pii/S2949928326000532?dgcid=rss_sd_all}
}